Roche: Key Takeaways from our 2026 CEO Call

J.P. Morgan hosted a conference call on September 8, 2026 with Roche CEO Thomas Schinecker and Head of Investor Relations Bruno Eschli as part of its 2026 Conference Call Series; the report summarizes the key takeaways and maintains a Neutral rating on Roche. Management reiterated that Roche's pipeline includes roughly 19 new molecular entities expected to read out Phase III trials through 2030 with launch potential, which should support Pharma growth into the 2030s, and reaffirmed guidance for "at least stable" Pharma margins. Management pointed out that Roche does not face a near-term patent cliff and sees no scenario of decline in the on-market Pharma portfolio, with the pipeline providing incremental growth;